Vision Disorders: Clinical Trials

6 trials for Vision Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 terminated. 6 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Terminated 6
Phase 23Terminated 3

Follow Vision Disorders: new trials by email Literature Review of Vision Disorders trials Research Report on Vision Disorders

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Proof of Concept Study of Binocular Videogames Versus Patching for Amblyopia
Binocular video games, Patching of the sound eye - Amblyopia
Phase 1TerminatedNovartis Pharmaceuticals272021-06-302023-05-23
Extension Study to Study PQ-110-001 (NCT03140969)
QR-110 - Leber Congenital Amaurosis 10, Blindness
Phase 1 / Phase 2TerminatedLaboratoires Thea92019-05-132024-10-15
BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES
BIIB092, Placebo - Primary Tauopathies, Corticobasal Degeneration Syndrome
Phase 1TerminatedUniversity of California, San Francisco222018-09-122019-12-19
Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene
AAV2/5-hPDE6B - Retinitis Pigmentosa
Phase 1 / Phase 2TerminatedeyeDNA Therapeutics192017-11-062025-12-18
Dichoptic Virtual Reality Therapy for Amblyopia in Adults
Dichoptic therapy, Patching therapy, Dioptic (non-dichoptic) therapy - Amblyopia, Anisometropia
Phase 1TerminatedUniversity of California, San Francisco172014-10-012017-05-03
Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B
SAR421869 - Usher Syndrome, Retinitis Pigmentosa
Phase 1 / Phase 2TerminatedSanofi92012-03-262022-04-28

Narrower conditions

Eye Diseases (3)  ·  Amblyopia (2)  ·  Eye Diseases, Hereditary (2)  ·  Retinal Diseases (2)  ·  Retinitis Pigmentosa (2)  ·  Anisometropia (1)  ·  Blindness (1)  ·  Color Vision Defects (1)  ·  Eye Abnormalities (1)  ·  Leber Congenital Amaurosis (1)  ·  Leber Congenital Amaurosis 10 (1)  ·  Meckel Syndrome, Type 4 (1)  ·  Neurologic Manifestations (1)  ·  Optic Atrophy, Hereditary, Leber (1)

Broader conditions

Nervous System Diseases (6)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Signs and Symptoms (6)  ·  Neurologic Manifestations (5)  ·  Sensation Disorders (5)  ·  Brain Diseases (3)  ·  Central Nervous System Diseases (3)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  Eye Diseases (3)  ·  Genetic Diseases, Inborn (3)  ·  Congenital Abnormalities (2)  ·  Cranial Nerve Diseases (2)  ·  Eye Diseases, Hereditary (2)  ·  Metabolic Diseases (2)

Interventions

Therapeutics (1)  ·  gosuranemab (1)

Sponsors

University of California, San Francisco (2)  ·  Laboratoires Thea (1)  ·  Novartis Pharmaceuticals (1)  ·  Sanofi (1)  ·  eyeDNA Therapeutics (1)

Countries

United States (5)  ·  France (2)  ·  Australia (1)  ·  Belgium (1)  ·  Canada (1)

Top investigators

Adam Boxer, MD, PhD (1)  ·  Jose-Alain Sahel, MD, PhD (1)  ·  Richard Weleber, MD (1)

Results publications

PMID 22828504, PMID 24705452, PMID 26857842, PMID 30646425

NIH funding

2016 (1), 2018 (1)